Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Biopharma_Watch Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1734221906151165952.png) BiopharmaWatch [@Biopharma_Watch](/creator/twitter/Biopharma_Watch) on x XXX followers
Created: 2025-07-21 15:45:09 UTC

$ALKS   [26.50$]   [-9.31%]   [July 21, 2025]
Alkermes Announces Positive Topline Results From Vibrance-1 Phase X Study of Once-Daily Alixorexton in Patients With Narcolepsy Type X


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947321959748075912/c:line.svg)

**Related Topics**
[$alks](/topic/$alks)

[Post Link](https://x.com/Biopharma_Watch/status/1947321959748075912)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Biopharma_Watch Avatar BiopharmaWatch @Biopharma_Watch on x XXX followers Created: 2025-07-21 15:45:09 UTC

$ALKS [26.50$] [-9.31%] [July 21, 2025] Alkermes Announces Positive Topline Results From Vibrance-1 Phase X Study of Once-Daily Alixorexton in Patients With Narcolepsy Type X

XXX engagements

Engagements Line Chart

Related Topics $alks

Post Link

post/tweet::1947321959748075912
/post/tweet::1947321959748075912